GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (OSTO:ASAP) » Definitions » Additional Paid-In Capital

Asarina Pharma AB (OSTO:ASAP) Additional Paid-In Capital : kr277.68 Mil(As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Asarina Pharma AB Additional Paid-In Capital?


Asarina Pharma AB's quarterly additional paid-in capital increased from Dec. 2022 (kr277.68 Mil) to Jun. 2023 (kr278.05 Mil) but then stayed the same from Jun. 2023 (kr278.05 Mil) to Dec. 2023 (kr277.68 Mil).

Asarina Pharma AB's annual additional paid-in capital increased from Dec. 2021 (kr272.81 Mil) to Dec. 2022 (kr277.68 Mil) but then stayed the same from Dec. 2022 (kr277.68 Mil) to Dec. 2023 (kr277.68 Mil).

Asarina Pharma AB Additional Paid-In Capital Historical Data

The historical data trend for Asarina Pharma AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Additional Paid-In Capital Chart

Asarina Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 264.50 272.81 272.81 277.68 277.68

Asarina Pharma AB Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 272.81 272.81 277.68 278.05 277.68

Asarina Pharma AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Asarina Pharma AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Asarina Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (OSTO:ASAP) » Definitions » Additional Paid-In Capital
Comparable Companies
XSAT:ALTE OSTO:CYXO OSTO:DIABIO OSTO:REDW OSTO:PHARM OSTO:AMNI XSAT:PHAL OSTO:LIDDS OSTO:SPAGO OSTO:CLINE B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Website
https://www.asarinapharma.com
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB Headlines

No Headlines